Sncb Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| SNCB | |
|---|---|
| Full Name | Beta-Synuclein |
| Symbol | SNCB |
| Chromosome | 5q35.2 |
| NCBI Gene ID | 6627 |
| OMIM ID | 163570 |
| Ensembl ID | ENSG00000074370 |
| UniProt ID | Q9NQ88 |
| Associated Diseases | Parkinson's Disease, Lewy Body Dementia, Multiple System Atrophy |
SNCB (Beta-Synuclein) encodes beta-synuclein, a member of the synuclein family of proteins that includes alpha-synuclein (SNCA) and gamma-synuclein (SNCG). Unlike its more famous counterpart alpha-synuclein, beta-synuclein is considered to have neuroprotective properties and inhibits the aggregation of alpha-synuclein.
Beta-synuclein is a soluble cytoplasmic protein predominantly expressed in neurons:
In the nervous system, beta-synuclein appears to play a protective role:
Beta-synuclein has a distinct expression pattern from alpha-synuclein:
| Approach | Description | Status |
|---|---|---|
| Beta-Synuclein Overexpression | Gene therapy to increase protective beta-synuclein | Preclinical |
| Small Molecule Stabilizers | Stabilize protective conformation | Research |
| Alpha-Synuclein Aggregation Inhibitors | Based on beta-synuclein mechanism | Clinical trials |
The study of Sncb Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
SNCB is expressed predominantly in the nervous system, particularly in:
The protein is localized to presynaptic terminals, where it colocalizes with alpha-synuclein.
Beta-synuclein shares structural homology with alpha-synuclein but lacks the NAC (non-Aβ component) region responsible for aggregation. Key functions include:
In PD, beta-synuclein may play protective roles:
Beta-synuclein is a component of Lewy bodies, though less abundant than alpha-synuclein. Its role in DLB pathogenesis includes:
Beta-synuclein inclusions are found in MSA, potentially through:
| Strategy | Rationale | Status |
|---|---|---|
| Gene therapy | Increase SNCB expression | Preclinical |
| Protein-based therapy | Exogenous beta-synuclein | Research |
| Small molecules | Modulate synuclein interactions | Experimental |
Withers GS, et al. (1997). "Beta-synuclein: localization to the nucleus and description in brain." Journal of Comparative Neurology 387(3): 402-417. ↩︎
Hashimoto M, et al. (2001). "Beta-synuclein inhibits alpha-synuclein aggregation." Neuron 32(2): 213-223. ↩︎
Uversky VN, et al. (2002). "Acetylation of beta-synuclein." Journal of Biological Chemistry 277(14): 11970-11978. ↩︎
Fan Y, et al. (2006). "Beta-synuclein in neurodegeneration." Neurobiology of Aging 27(6): 798-806. ↩︎
Beyer K, et al. (2008). "Differential expression of beta-synuclein in neurodegenerative diseases." Acta Neuropathologica 115(5): 535-546. ↩︎